Healthcare / Drug Manufacturers - Specialty & GenericBSE
$24.56
+0.06 (+0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-27.8M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$491M
P/E
61.4x
↑EV/EBITDA
31.5x
↑ROE
1.8%
↑Gross Margin
31.6%
↓Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.4%
FCF CAGR
—
FCF margin
-55.2%
FCF / Net income
-23.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $166.7M · net income $3.9M · FCF $-92.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $166.7M | $166.7M | $132.2M | $132.3M | $95.5M |
| Net Income | $3.9M | $3.9M | $4.1M | $15.8M | $-736000.00 |
| EBITDA | $16.8M | $16.8M | $20.0M | $17.4M | $8.1M |
| EPS | 0.20 | 0.20 | 0.21 | 0.76 | -0.06 |
| Gross Margin | 31.6% | 31.6% | 31.0% | 30.2% | 27.5% |
| Operating Margin | -0.7% | -0.7% | -0.8% | 1.4% | -11.4% |
| Net Margin | 2.3% | 2.3% | 3.1% | 12.0% | -0.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-92.0M | $-92.0M | $20.7M | $-27.8M | $2.3M |
| Returns | |||||
| ROE | 1.8% | 1.8% | 1.9% | 7.4% | -0.5% |
| Valuation | |||||
| P/E | 61.40 | 61.40 | 114.76 | 13.49 | — |
| EV/EBITDA | 31.47 | 31.47 | 23.97 | 9.71 | 9.86 |
| P/B | 2.21 | 2.21 | 2.21 | 0.96 | 0.60 |
| Growth & Yield | |||||
| Revenue Growth | 26.1% | 26.1% | -0.0% | 38.5% | — |
| EPS Growth | -4.8% | -4.8% | -72.4% | 1481.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
121.7%
EPS terminal req.
$2.18
Spread vs growth
-126.5%
5Y implied EPS CAGR
67.5%
EPS terminal req.
$2.64
Spread vs growth
-72.3%
10Y implied EPS CAGR
35.7%
EPS terminal req.
$4.25
Spread vs growth
-40.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+69.0%
Start / end P/E
69.2x → 122.8x
EPS bridge
0.21 → 0.20
Residual
-3.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.